Tesamorelin vs Pramlintide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Full details →

Pramlintide

Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.

Full details →

Side-by-Side Comparison

AspectTesamorelinPramlintide
MechanismStimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy.
Typical DosageFDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories.
AdministrationSubcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin.
Side EffectsCommon side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time.
Best For

What They Have in Common

Both Tesamorelin and Pramlintide are commonly used for:

Key Differences

Ready to Learn More?